Atara Biotherapeutics, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • ATRA
  • 1d-4.15%
  • 1w-9.44%
  • 1m9.31%
  • 1y-74.77%
ATH
  • ATH Price$64.02
  • ATH Date2015-04-23
  • % since ATH-98.94%
  • % to ATH9,334.13%
ATL
  • ATL Price$0.23
  • ATL Date2023-11-10
  • % from ATL195.30%
  • Last Low Price$0.2298
  • Last Low Date2023-11-10
  • % From Last Low195.30%
IPO
  • IPO Price$9.89
  • % Current ROI USD-93.14%
  • ATH Price$64.02
  • % ROI ATH 2,785,900.78%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="ATRA"]

Key Data [addtoany]

Current price $0.6786
Sector Healthcare
Industry Biotechnology
Today's High/Low $0.71/$0.65
Volume 1,721,546.00
Previous Close $0.708
52 Week High/Low $3.06/$0.1986
Market Cap 84,506,176.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $-0.55
Annualized Dividend $0
$0.6786
[addtoany]

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States.
It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.
The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis.
In addition, it develops ATA2321 for acute myeloid leukemia; and ATA368 for human papillomavirus. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H.
Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors.
The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity